首页 > 最新文献

Journal of Surgical Oncology最新文献

英文 中文
Correction to "Prognostic Utility of Circulating Tumor DNA Methylation Analysis in Stage IV Colorectal Cancer". 修正“循环肿瘤DNA甲基化分析在IV期结直肠癌中的预后效用”。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-11 DOI: 10.1002/jso.70186
{"title":"Correction to \"Prognostic Utility of Circulating Tumor DNA Methylation Analysis in Stage IV Colorectal Cancer\".","authors":"","doi":"10.1002/jso.70186","DOIUrl":"https://doi.org/10.1002/jso.70186","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145952454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insulin-Dependence and Survival in Pancreatic Neuroendocrine Tumors: Results From the US-NTSG Group 胰腺神经内分泌肿瘤的胰岛素依赖和生存:来自US-NTSG组的结果。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-11 DOI: 10.1002/jso.70174
Muhammad Bilal Mirza, Jordan J. Baechle, Paula Marincola Smith, Danish Ali, Mary Dillhoff, George Poultsides, Flavio G. Rocha, Clifford S. Cho, Emily R. Winslow, Ryan C. Fields, Shishir K. Maithel, Kamran Idrees

Introduction

PNETs are rare pancreatic malignancies originating from islet cells and exhibit a strong co-occurrence with Diabetes Mellitus (DM), associated with worse survival outcomes. However, studies have yet to delineate the impact of insulin dependent (IDDM) and non-insulin dependent (NIDDM) on poor oncological outcomes.

Methods

Utilizing the U.S. Neuroendocrine Tumor Study Group database (1999-2016), we performed a retrospective cohort study of adult patients who underwent primary surgical resection of PNETs. Patients were categorized based on preoperative diagnosis into non-DM, NIDDM, and IDDM cohorts. We used the Kaplan-Meier method and log-rank test to study cancer-specific survival (CSS). Cox proportional Hazards models were used to assess the impact of IDDM on CSS.

Results

Of the 1122 patients included in the analysis, 870 (77%) were non-DM, 168 (15%) were NIDDM, and 84 (8%) were IDDM. The groups were similar in tumor stage and grade. However, they differed in sex, BMI, age, ASA class, tumor location, preoperative HbA1c, and serum glucose (p-value < 0.05). Patients with IDDM had significantly decreased 5-year CSS compared to patients without IDDM (CSS: IDDM 85%, NIDDM 94%, non-DM 93%, NIDDM + non-DM 93%; p < 0.01). On multivariate analysis, IDDM was independently associated with worse CSS (HR 2.27, 95% Confidence Interval 1.15−4.45, p = 0.02).

Conclusion

Insulin dependence is associated with worse cancer-specific survival in PNET patients following surgical resection compared to PNET patients with NIDDM or without DM.

PNETs是一种罕见的胰腺恶性肿瘤,起源于胰岛细胞,并与糖尿病(DM)共同发生,与较差的生存结果相关。然而,研究尚未描述胰岛素依赖型(IDDM)和非胰岛素依赖型(NIDDM)对不良肿瘤预后的影响。方法:利用美国神经内分泌肿瘤研究小组数据库(1999-2016),我们对接受原发性PNETs手术切除的成年患者进行了回顾性队列研究。根据术前诊断将患者分为非糖尿病组、非糖尿病组和非糖尿病组。我们采用Kaplan-Meier法和log-rank检验来研究癌症特异性生存(CSS)。采用Cox比例风险模型评估IDDM对CSS的影响。结果:纳入分析的1122例患者中,870例(77%)为非糖尿病,168例(15%)为NIDDM, 84例(8%)为IDDM。两组肿瘤分期、分级相似。然而,他们在性别、BMI、年龄、ASA类别、肿瘤位置、术前HbA1c和血清葡萄糖方面存在差异(p值)。结论:与合并NIDDM或无DM的PNET患者相比,手术切除后PNET患者的胰岛素依赖与更差的癌症特异性生存相关。
{"title":"Insulin-Dependence and Survival in Pancreatic Neuroendocrine Tumors: Results From the US-NTSG Group","authors":"Muhammad Bilal Mirza,&nbsp;Jordan J. Baechle,&nbsp;Paula Marincola Smith,&nbsp;Danish Ali,&nbsp;Mary Dillhoff,&nbsp;George Poultsides,&nbsp;Flavio G. Rocha,&nbsp;Clifford S. Cho,&nbsp;Emily R. Winslow,&nbsp;Ryan C. Fields,&nbsp;Shishir K. Maithel,&nbsp;Kamran Idrees","doi":"10.1002/jso.70174","DOIUrl":"10.1002/jso.70174","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>PNETs are rare pancreatic malignancies originating from islet cells and exhibit a strong co-occurrence with Diabetes Mellitus (DM), associated with worse survival outcomes. However, studies have yet to delineate the impact of insulin dependent (IDDM) and non-insulin dependent (NIDDM) on poor oncological outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Utilizing the U.S. Neuroendocrine Tumor Study Group database (1999-2016), we performed a retrospective cohort study of adult patients who underwent primary surgical resection of PNETs. Patients were categorized based on preoperative diagnosis into non-DM, NIDDM, and IDDM cohorts. We used the Kaplan-Meier method and log-rank test to study cancer-specific survival (CSS). Cox proportional Hazards models were used to assess the impact of IDDM on CSS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 1122 patients included in the analysis, 870 (77%) were non-DM, 168 (15%) were NIDDM, and 84 (8%) were IDDM. The groups were similar in tumor stage and grade. However, they differed in sex, BMI, age, ASA class, tumor location, preoperative HbA1c, and serum glucose (<i>p</i>-value &lt; 0.05). Patients with IDDM had significantly decreased 5-year CSS compared to patients without IDDM (CSS: IDDM 85%, NIDDM 94%, non-DM 93%, NIDDM + non-DM 93%; <i>p</i> &lt; 0.01). On multivariate analysis, IDDM was independently associated with worse CSS (HR 2.27, 95% Confidence Interval 1.15−4.45, <i>p</i> = 0.02).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Insulin dependence is associated with worse cancer-specific survival in PNET patients following surgical resection compared to PNET patients with NIDDM or without DM.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"133 2","pages":"153-160"},"PeriodicalIF":1.9,"publicationDate":"2026-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12863235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145952512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to "Chemotherapy Switch for Non-Response or Progression on Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma". 修正“胰腺腺癌新辅助化疗无反应或进展的化疗切换”。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-11 DOI: 10.1002/jso.70187
{"title":"Correction to \"Chemotherapy Switch for Non-Response or Progression on Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma\".","authors":"","doi":"10.1002/jso.70187","DOIUrl":"https://doi.org/10.1002/jso.70187","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145952459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular Reconstruction in Extremity Soft Tissue Sarcomas: A Systematic Review and Single-Arm Meta-Analysis. 四肢软组织肉瘤血管重建:一项系统综述和单组荟萃分析。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-08 DOI: 10.1002/jso.70194
Lucas Monteiro Delgado, Bernardo Fontel Pompeu, Vinícius Dos Santos Macedo, Gabriel Henrique Acedo Martins, Eric Pasqualotto, Matheus Reginato Araujo, Julia Hoici Brunini, Victor Andrade Nunes, Cláudia Theis, Samuel Aguiar Junior

Introduction: The management of extremity soft tissue sarcomas (STS) involving major vessels presents unique challenges, historically leading to amputation. Advances in vascular reconstruction have enabled limb-sparing surgery (LSS), but outcomes and perioperative risks remain uncertain. This systematic review and meta-analysis aimed to evaluate oncologic results following LSS with vascular reconstruction in extremity STS.

Methods: A systematic review and single-arm meta-analysis were performed according to PRISMA guidelines, with registration in PROSPERO. PubMed, Embase, and Cochrane Library were searched from inception to June 2025 for studies reporting outcomes in patients with extremity STS undergoing LSS with vascular reconstruction. Pooled analyses estimated limb salvage, survival, and complication rates using random-effects models.

Results: Thirty-one studies comprising 520 patients were included. Approximately 58% were male, with a mean age ranging from 29.3 to 59 years. The most common tumor localizations were the thigh (59.5%), inguinal region (15.9%), and popliteal fossa (8.6%). Liposarcoma (24.0%), synovial sarcoma (19.6%), and osteosarcoma (14.8%) were the most frequent histological subtypes. The pooled limb salvage rate was 89% (95% CI, 86%-92%), while amputation occurred in 10% (95% CI, 8%-14%). One- and 5-year overall survival rates were 89% and 62%, respectively, with disease-free survival rates of 74% and 55%. Major complications included graft thrombosis (19%), wound complications (29%), and wound infection (22%).

Conclusions: Limb-sparing surgery with vascular reconstruction is effective for extremity STS involving major vessels, enabling high limb salvage and favorable long-term survival without compromising oncologic outcomes. However, substantial perioperative morbidity persists, underscoring the need for multidisciplinary care, careful patient selection, and prospective studies to refine indications and enhance quality of life.

简介:四肢软组织肉瘤(STS)涉及主要血管的管理提出了独特的挑战,历史上导致截肢。血管重建的进步使保肢手术(LSS)成为可能,但结果和围手术期风险仍然不确定。本系统综述和荟萃分析旨在评估肢体STS患者LSS合并血管重建后的肿瘤学结果。方法:根据PRISMA指南进行系统评价和单臂荟萃分析,并在PROSPERO注册。PubMed、Embase和Cochrane图书馆检索了从成立到2025年6月报道肢体STS患者行LSS合并血管重建结果的研究。采用随机效应模型进行汇总分析,估计残肢保留、生存率和并发症发生率。结果:纳入了31项研究,包括520例患者。约58%为男性,平均年龄在29.3岁至59岁之间。最常见的肿瘤定位是大腿(59.5%)、腹股沟区(15.9%)和腘窝(8.6%)。脂肪肉瘤(24.0%)、滑膜肉瘤(19.6%)和骨肉瘤(14.8%)是最常见的组织学亚型。合并肢体保留率为89% (95% CI, 86%-92%),而截肢发生率为10% (95% CI, 8%-14%)。1年和5年总生存率分别为89%和62%,无病生存率为74%和55%。主要并发症包括移植物血栓形成(19%)、伤口并发症(29%)和伤口感染(22%)。结论:保留肢体的血管重建手术对涉及大血管的肢体STS是有效的,可以在不影响肿瘤预后的情况下实现高肢体保留和良好的长期生存。然而,大量围手术期发病率持续存在,强调需要多学科护理,仔细选择患者,并进行前瞻性研究以改善适应症和提高生活质量。
{"title":"Vascular Reconstruction in Extremity Soft Tissue Sarcomas: A Systematic Review and Single-Arm Meta-Analysis.","authors":"Lucas Monteiro Delgado, Bernardo Fontel Pompeu, Vinícius Dos Santos Macedo, Gabriel Henrique Acedo Martins, Eric Pasqualotto, Matheus Reginato Araujo, Julia Hoici Brunini, Victor Andrade Nunes, Cláudia Theis, Samuel Aguiar Junior","doi":"10.1002/jso.70194","DOIUrl":"https://doi.org/10.1002/jso.70194","url":null,"abstract":"<p><strong>Introduction: </strong>The management of extremity soft tissue sarcomas (STS) involving major vessels presents unique challenges, historically leading to amputation. Advances in vascular reconstruction have enabled limb-sparing surgery (LSS), but outcomes and perioperative risks remain uncertain. This systematic review and meta-analysis aimed to evaluate oncologic results following LSS with vascular reconstruction in extremity STS.</p><p><strong>Methods: </strong>A systematic review and single-arm meta-analysis were performed according to PRISMA guidelines, with registration in PROSPERO. PubMed, Embase, and Cochrane Library were searched from inception to June 2025 for studies reporting outcomes in patients with extremity STS undergoing LSS with vascular reconstruction. Pooled analyses estimated limb salvage, survival, and complication rates using random-effects models.</p><p><strong>Results: </strong>Thirty-one studies comprising 520 patients were included. Approximately 58% were male, with a mean age ranging from 29.3 to 59 years. The most common tumor localizations were the thigh (59.5%), inguinal region (15.9%), and popliteal fossa (8.6%). Liposarcoma (24.0%), synovial sarcoma (19.6%), and osteosarcoma (14.8%) were the most frequent histological subtypes. The pooled limb salvage rate was 89% (95% CI, 86%-92%), while amputation occurred in 10% (95% CI, 8%-14%). One- and 5-year overall survival rates were 89% and 62%, respectively, with disease-free survival rates of 74% and 55%. Major complications included graft thrombosis (19%), wound complications (29%), and wound infection (22%).</p><p><strong>Conclusions: </strong>Limb-sparing surgery with vascular reconstruction is effective for extremity STS involving major vessels, enabling high limb salvage and favorable long-term survival without compromising oncologic outcomes. However, substantial perioperative morbidity persists, underscoring the need for multidisciplinary care, careful patient selection, and prospective studies to refine indications and enhance quality of life.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long Term Metabolic Outcomes Following Pancreatectomy and Autologous Islet Transplantation: Systematic Review and Meta-Analysis. 胰腺切除术和自体胰岛移植后的长期代谢结果:系统回顾和荟萃分析。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-08 DOI: 10.1002/jso.70193
Daniel L Hughes, Caterina Di Bella, Benedetta Quaratino, Pietro Rigo, Giulia Cirillo, Gioia Sgrinzato, Umberto Cillo, Lucrezia Furian, Giovanni Marchegiani

This systematic review and meta-analysis assessed long-term outcomes following total pancreatectomy with islet autotransplantation (TPIAT). Seventeen studies including 1332 patients were analyzed. The pooled insulin independence rate was 34%, with higher rates for non-chronic pancreatitis indications (68%) versus chronic pancreatitis (33%). TPIAT is effective in preserving endocrine function. Further studies are needed to validate outcomes across extended indications and to standardize reporting, incorporating metabolic markers and patient-reported quality-of-life endpoints over long-term follow-up.

本系统综述和荟萃分析评估了全胰腺切除术合并胰岛自体移植(TPIAT)后的长期结果。17项研究包括1332例患者进行了分析。合并胰岛素独立率为34%,非慢性胰腺炎适应症(68%)高于慢性胰腺炎适应症(33%)。TPIAT对维持内分泌功能有效。需要进一步的研究来验证扩展适应症的结果,并标准化报告,在长期随访中纳入代谢标志物和患者报告的生活质量终点。
{"title":"Long Term Metabolic Outcomes Following Pancreatectomy and Autologous Islet Transplantation: Systematic Review and Meta-Analysis.","authors":"Daniel L Hughes, Caterina Di Bella, Benedetta Quaratino, Pietro Rigo, Giulia Cirillo, Gioia Sgrinzato, Umberto Cillo, Lucrezia Furian, Giovanni Marchegiani","doi":"10.1002/jso.70193","DOIUrl":"https://doi.org/10.1002/jso.70193","url":null,"abstract":"<p><p>This systematic review and meta-analysis assessed long-term outcomes following total pancreatectomy with islet autotransplantation (TPIAT). Seventeen studies including 1332 patients were analyzed. The pooled insulin independence rate was 34%, with higher rates for non-chronic pancreatitis indications (68%) versus chronic pancreatitis (33%). TPIAT is effective in preserving endocrine function. Further studies are needed to validate outcomes across extended indications and to standardize reporting, incorporating metabolic markers and patient-reported quality-of-life endpoints over long-term follow-up.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Systematic Mapping Review of Core Outcome Reporting in Surgical Research for Oesophageal Cancer. 食管癌外科研究核心结果报告的系统制图综述。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-07 DOI: 10.1002/jso.70173
Nadia Matias, Anie Naqvi, Jack Thomson, Roukia Techache, Kerry Avery, Natalie Blencowe, Rhiannon Macefield, Bilal Alkhaffaf

Oesophageal carcinoma is a rising global health burden, with surgical resection and perioperative chemotherapy forming the cornerstone of curative treatment. However, uncertainty persists regarding the optimal surgical approach, partly due to heterogeneity in outcome reporting, which hinders data synthesis and evidence-based decision-making. To address this, a core outcome set (COS) for oesophageal cancer surgery was developed through international consensus among clinicians and patients. This study systematically evaluates the uptake of these core outcomes in contemporary surgical research. A systematic review was conducted of randomised controlled trials and prospective cohort studies investigating oesophagectomy for oesophageal cancer, published between 2010 and 2024. The reporting of ten COS-recommended outcomes was assessed across eligible studies. Fifty-eight studies involving 22 260 patients were included (39 cohort studies; 19 RCTs). No study reported all 10 core outcomes. The median number of core outcomes reported was 4 (interquartile range 3-5). The frequency of individual core outcome reporting was as follows: in-hospital mortality (86%), conduit necrosis/leak (81%), respiratory complications (79%), overall survival (30%), ability to eat and drink (44%), quality of life (26%), inoperability (23%), reflux symptoms (21%), severe nutritional effects (19%), and need for reintervention (16%). No improvement in core outcome reporting was observed over the study period. Promoting COS implementation and improving methodological rigour is essential to ensure that future research reflects the priorities of both clinicians and patients, and facilitates meaningful evidence synthesis.

食管癌是一个日益严重的全球健康负担,手术切除和围手术期化疗是根治性治疗的基石。然而,关于最佳手术方法的不确定性仍然存在,部分原因是结果报告的异质性,这阻碍了数据合成和循证决策。为了解决这个问题,通过临床医生和患者之间的国际共识,制定了食管癌手术的核心结局集(COS)。本研究系统地评估了这些核心结果在当代外科研究中的应用。对2010年至2024年间发表的调查食管癌食管癌切除术的随机对照试验和前瞻性队列研究进行了系统回顾。在符合条件的研究中评估了cos推荐的十个结果的报告。纳入58项研究,涉及22260例患者(39项队列研究;19项随机对照试验)。没有研究报告了全部10项核心结果。报告的核心结果中位数为4个(四分位数范围为3-5)。个别核心结局报告的频率如下:住院死亡率(86%),导管坏死/渗漏(81%),呼吸系统并发症(79%),总生存率(30%),饮食能力(44%),生活质量(26%),不可操作性(23%),反流症状(21%),严重营养不良(19%),需要再干预(16%)。在研究期间,没有观察到核心结果报告的改善。促进COS的实施和提高方法的严谨性对于确保未来的研究反映临床医生和患者的优先事项并促进有意义的证据合成至关重要。
{"title":"A Systematic Mapping Review of Core Outcome Reporting in Surgical Research for Oesophageal Cancer.","authors":"Nadia Matias, Anie Naqvi, Jack Thomson, Roukia Techache, Kerry Avery, Natalie Blencowe, Rhiannon Macefield, Bilal Alkhaffaf","doi":"10.1002/jso.70173","DOIUrl":"https://doi.org/10.1002/jso.70173","url":null,"abstract":"<p><p>Oesophageal carcinoma is a rising global health burden, with surgical resection and perioperative chemotherapy forming the cornerstone of curative treatment. However, uncertainty persists regarding the optimal surgical approach, partly due to heterogeneity in outcome reporting, which hinders data synthesis and evidence-based decision-making. To address this, a core outcome set (COS) for oesophageal cancer surgery was developed through international consensus among clinicians and patients. This study systematically evaluates the uptake of these core outcomes in contemporary surgical research. A systematic review was conducted of randomised controlled trials and prospective cohort studies investigating oesophagectomy for oesophageal cancer, published between 2010 and 2024. The reporting of ten COS-recommended outcomes was assessed across eligible studies. Fifty-eight studies involving 22 260 patients were included (39 cohort studies; 19 RCTs). No study reported all 10 core outcomes. The median number of core outcomes reported was 4 (interquartile range 3-5). The frequency of individual core outcome reporting was as follows: in-hospital mortality (86%), conduit necrosis/leak (81%), respiratory complications (79%), overall survival (30%), ability to eat and drink (44%), quality of life (26%), inoperability (23%), reflux symptoms (21%), severe nutritional effects (19%), and need for reintervention (16%). No improvement in core outcome reporting was observed over the study period. Promoting COS implementation and improving methodological rigour is essential to ensure that future research reflects the priorities of both clinicians and patients, and facilitates meaningful evidence synthesis.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brazilian Society of Surgical Oncology: Guidelines and Consensus Statement for Palliative Surgery in Oncology. 巴西肿瘤外科学会:肿瘤姑息性手术指南和共识声明。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-07 DOI: 10.1002/jso.70189
Audrey Cabral Ferreira de Oliveira, Jordana Henz Hammes, Isabela Maria Alves de Almeida Oliva, Lara Andrade Mendes Mangieri, Ronald Enrique Delgado Bocanegra, Marcos Gonçalves Adriano Junior, Ana Caroline Fonseca Alves, Eliel Oliveira de Araujo, Jairo Cerqueira de Almeida Teixeira, Patricia Isabel Bahia Mendes Freire, Larissa de Jesus Almeida, Raquel Lacerda Dantas de Farias, Heládio Feitosa E Castro Neto, Alexandre Ferreira Oliveira, Reitan Ribeiro, Rodrigo Nascimento Pinheiro

Background and objective: Palliative surgery in oncology aims to relieve symptoms, improve quality of life, and respect patient autonomy in advanced cancer. This study aimed to develop evidence-based recommendations for safely indicating and performing palliative surgeries in Brazil, considering clinical, ethical, and multidisciplinary aspects.

Methods: A modified Delphi consensus was conducted with nine experts from the Brazilian Society of Surgical Oncology, including surgical and clinical oncologists, palliative care specialists, and a psychologist. Sixteen key recommendations were formulated based on literature review and a national survey identifying gaps in training, communication, and technical safety. Consensus was defined as ≥ 80% agreement, achieved in a single round.

Results: Recommendations emphasize individualized patient selection based on functional status, frailty, prognosis, and symptom severity. Multidisciplinary evaluation, shared decision-making, clear communication, and consideration of minimally invasive techniques were prioritized. Palliative procedures focus on symptom control rather than survival extension, with evidence supporting improved quality of life, reduced hospital admissions, and enhanced oral intake.

Conclusions: Palliative surgery should be guided by strict clinical criteria, multidisciplinary planning, and patient-centered communication. Active patient participation, ethical deliberation, and evidence-based practices ensure safe, effective, and humanized care, avoiding futile or disproportionate interventions.

背景与目的:肿瘤姑息性手术旨在缓解晚期肿瘤患者的症状,提高生活质量,并尊重患者的自主权。本研究旨在考虑临床、伦理和多学科方面,为巴西安全指示和实施姑息性手术制定循证建议。方法:与来自巴西外科肿瘤学会的9位专家进行了修改的德尔菲共识,包括外科和临床肿瘤学家、姑息治疗专家和一位心理学家。根据文献综述和一项确定培训、沟通和技术安全方面差距的全国调查,制定了16项关键建议。共识被定义为≥80%的共识,在单轮中达成。结果:建议强调基于功能状态、虚弱、预后和症状严重程度的个体化患者选择。多学科评估、共同决策、明确沟通和考虑微创技术是优先考虑的。姑息治疗程序侧重于症状控制,而不是延长生存期,有证据支持改善生活质量、减少住院次数和增加口服摄入量。结论:姑息性手术应以严格的临床标准、多学科规划和以患者为中心的沟通为指导。积极的患者参与、伦理审议和循证实践确保了安全、有效和人性化的护理,避免了无效或不成比例的干预。
{"title":"Brazilian Society of Surgical Oncology: Guidelines and Consensus Statement for Palliative Surgery in Oncology.","authors":"Audrey Cabral Ferreira de Oliveira, Jordana Henz Hammes, Isabela Maria Alves de Almeida Oliva, Lara Andrade Mendes Mangieri, Ronald Enrique Delgado Bocanegra, Marcos Gonçalves Adriano Junior, Ana Caroline Fonseca Alves, Eliel Oliveira de Araujo, Jairo Cerqueira de Almeida Teixeira, Patricia Isabel Bahia Mendes Freire, Larissa de Jesus Almeida, Raquel Lacerda Dantas de Farias, Heládio Feitosa E Castro Neto, Alexandre Ferreira Oliveira, Reitan Ribeiro, Rodrigo Nascimento Pinheiro","doi":"10.1002/jso.70189","DOIUrl":"10.1002/jso.70189","url":null,"abstract":"<p><strong>Background and objective: </strong>Palliative surgery in oncology aims to relieve symptoms, improve quality of life, and respect patient autonomy in advanced cancer. This study aimed to develop evidence-based recommendations for safely indicating and performing palliative surgeries in Brazil, considering clinical, ethical, and multidisciplinary aspects.</p><p><strong>Methods: </strong>A modified Delphi consensus was conducted with nine experts from the Brazilian Society of Surgical Oncology, including surgical and clinical oncologists, palliative care specialists, and a psychologist. Sixteen key recommendations were formulated based on literature review and a national survey identifying gaps in training, communication, and technical safety. Consensus was defined as ≥ 80% agreement, achieved in a single round.</p><p><strong>Results: </strong>Recommendations emphasize individualized patient selection based on functional status, frailty, prognosis, and symptom severity. Multidisciplinary evaluation, shared decision-making, clear communication, and consideration of minimally invasive techniques were prioritized. Palliative procedures focus on symptom control rather than survival extension, with evidence supporting improved quality of life, reduced hospital admissions, and enhanced oral intake.</p><p><strong>Conclusions: </strong>Palliative surgery should be guided by strict clinical criteria, multidisciplinary planning, and patient-centered communication. Active patient participation, ethical deliberation, and evidence-based practices ensure safe, effective, and humanized care, avoiding futile or disproportionate interventions.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145911933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Critical Appraisal of "Development of a Multivariable Machine Learning Model for the Prediction of Postoperative Ileus After Radical Cystectomy". 对“用于预测根治性膀胱切除术后肠梗阻的多变量机器学习模型的开发”的批判性评价。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-04 DOI: 10.1002/jso.70190
Hasan Nawaz Tahir, Muhammad Yousaf, Umema Tariq, Muhammad Bilal Arif, AmeerAli Abdul Hameed
{"title":"Critical Appraisal of \"Development of a Multivariable Machine Learning Model for the Prediction of Postoperative Ileus After Radical Cystectomy\".","authors":"Hasan Nawaz Tahir, Muhammad Yousaf, Umema Tariq, Muhammad Bilal Arif, AmeerAli Abdul Hameed","doi":"10.1002/jso.70190","DOIUrl":"https://doi.org/10.1002/jso.70190","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Repeat Core Needle Biopsy After Nondiagnostic Initial Biopsy for Soft Tissue and Bone Sarcoma: Systematic Review and Meta-Analysis. 在软组织和骨肉瘤的非诊断性初始活检后,重复核心针活检的作用:系统评价和荟萃分析。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2025-12-31 DOI: 10.1002/jso.70178
Imad Mirza, Cian M Hehir, Conor Farrell, Adil Mirza, Matthew Lee, Gary O'Toole, Alan P Molloy

Core needle biopsy (CNB) is the preferred diagnostic method for suspected soft tissue and bone sarcoma, but nondiagnostic results remain common. To clarify the role of repeat biopsy, we conducted a systematic review of studies reporting repeat CNB after an initial nondiagnostic CNB, searching MEDLINE, EMBASE and PubMed. Nine studies involving nearly 9757 initial CNBs were included. Meta-analysis showed a pooled diagnostic yield of 69% (95% CI: 0.564-0.819) for repeat CNB. Subgroup analyses demonstrated a significantly higher diagnostic yield in bone sarcoma (83.1%) compared with soft tissue sarcoma (48.5%). The repeat CNB rate following a nondiagnostic initial biopsy was 5.48%. This study represents the first systematic review and meta-analysis evaluating repeat CNB in this setting, and it highlights substantial variability in diagnostic yield between sarcoma subtypes. Further research focusing on repeat biopsy across specific sarcoma subgroups is warranted to guide clinical decision-making.

核心穿刺活检(CNB)是疑似软组织和骨肉瘤的首选诊断方法,但非诊断性结果仍然很常见。为了明确重复活检的作用,我们对报告首次非诊断性CNB后重复CNB的研究进行了系统回顾,检索了MEDLINE、EMBASE和PubMed。纳入了9项研究,涉及近9757个初始CNBs。荟萃分析显示,重复CNB的合并诊断率为69% (95% CI: 0.564-0.819)。亚组分析显示骨肉瘤的诊断率(83.1%)明显高于软组织肉瘤(48.5%)。非诊断性初始活检后的重复CNB率为5.48%。该研究首次对重复CNB进行了系统评价和荟萃分析,并强调了肉瘤亚型之间诊断率的显著差异。进一步的研究聚焦于特定肉瘤亚组的重复活检,以指导临床决策。
{"title":"Role of Repeat Core Needle Biopsy After Nondiagnostic Initial Biopsy for Soft Tissue and Bone Sarcoma: Systematic Review and Meta-Analysis.","authors":"Imad Mirza, Cian M Hehir, Conor Farrell, Adil Mirza, Matthew Lee, Gary O'Toole, Alan P Molloy","doi":"10.1002/jso.70178","DOIUrl":"https://doi.org/10.1002/jso.70178","url":null,"abstract":"<p><p>Core needle biopsy (CNB) is the preferred diagnostic method for suspected soft tissue and bone sarcoma, but nondiagnostic results remain common. To clarify the role of repeat biopsy, we conducted a systematic review of studies reporting repeat CNB after an initial nondiagnostic CNB, searching MEDLINE, EMBASE and PubMed. Nine studies involving nearly 9757 initial CNBs were included. Meta-analysis showed a pooled diagnostic yield of 69% (95% CI: 0.564-0.819) for repeat CNB. Subgroup analyses demonstrated a significantly higher diagnostic yield in bone sarcoma (83.1%) compared with soft tissue sarcoma (48.5%). The repeat CNB rate following a nondiagnostic initial biopsy was 5.48%. This study represents the first systematic review and meta-analysis evaluating repeat CNB in this setting, and it highlights substantial variability in diagnostic yield between sarcoma subtypes. Further research focusing on repeat biopsy across specific sarcoma subgroups is warranted to guide clinical decision-making.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy 预处理CA19-9可预测胰腺癌患者对新辅助治疗的最佳反应。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2025-12-31 DOI: 10.1002/jso.70179
Anthony Gebran, Asmita Chopra, Emile Farah, Sarah Hays, Kristen Ranson, Aram Rojas, Sebastiaan Ceuppens, Robin Schmitz, Hao Liu, Nikhil V. Tirukkovalur, Mark Talamonti, Kenneth K. Lee, Herbert J. Zeh, Carl Schmidt, Brian A. Boone, Melissa Hogg, Amer H. Zureikat, Patricio M. Polanco, Alessandro Paniccia

Background and Objectives

Pancreatic ductal adenocarcinoma (PDAC) is characterized by limited survival rates, yet patients who achieve optimal CA19-9 response to neoadjuvant therapy (NAT) exhibit improved survival. This study examines the association between initial CA19-9 levels and survival in PDAC patients who achieved CA19-9 normalization with systemic chemotherapy.

Methods

A retrospective, multi-institutional analysis of patients with resectable/borderline-resectable PDAC, who underwent NAT and curative-intent pancreatectomy at the University of Pittsburgh Medical Center, University of Texas Southwestern Medical Center, NorthShore University, and West Virginia University To contexualize thi between 2010 and 2022, was performed. CA19-9 secretors (> 37 U/mL, with total bilirubin < 2) at diagnosis, with optimal response to NAT (normalization and > 50% drop in CA19-9) were included. A cutoff for pre-NAT CA19-9 of 400 U/mL was determined to maximize sensitivity and specificity for survival benefit, and the cohort was accordingly divided into two groups. Kaplan–Meier and Cox proportional-hazards models were used for univariate and multivariable analyses.

Results

A total of 134 patients were included, 32 (23.9%) had a pre-NAT CA19-9 ≥ 400U/mL. DFS and OS were considerably higher among patients with pre-NAT CA19-9 < 400U/mL (median(95%CI) in months, DFS:19.8(16.0,33.4) versus 7.8(5.0,13.0); OS:49.0(34.5,70.7) versus 23.1(13.8,50.9)). On multivariable analysis, pre-NAT CA19-9 ≥ 400 U/mL was significantly associated with reduced DFS and OS (DFS:HR = 2.4, p = 0.001; OS:HR = 1.9, p = 0.028).

Conclusion

In this select cohort of PDAC patients with optimal NAT response, pre-NAT CA19-9 ≥ 400U/mL is strongly associated with decreased DFS and OS.

背景和目的:胰腺导管腺癌(PDAC)的特点是生存率有限,然而对新辅助治疗(NAT)达到最佳CA19-9反应的患者表现出生存率的提高。本研究探讨了通过全身化疗实现CA19-9正常化的PDAC患者初始CA19-9水平与生存之间的关系。方法:回顾性、多机构分析2010年至2022年间在匹兹堡大学医学中心、德克萨斯大学西南医学中心、北岸大学和西弗吉尼亚大学接受NAT和治愈性胰腺切除术的可切除/边缘性可切除PDAC患者。纳入CA19-9分泌物(> 37 U/mL,总胆红素CA19-9下降50%)。确定nat前CA19-9的临界值为400 U/mL,以最大限度地提高生存获益的敏感性和特异性,并相应地将队列分为两组。单变量和多变量分析采用Kaplan-Meier和Cox比例风险模型。结果:共纳入134例患者,nat前CA19-9≥400U/mL 32例(23.9%)。结论:在NAT反应最佳的PDAC患者中,NAT前CA19-9≥400U/mL与DFS和OS的降低密切相关。
{"title":"Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy","authors":"Anthony Gebran,&nbsp;Asmita Chopra,&nbsp;Emile Farah,&nbsp;Sarah Hays,&nbsp;Kristen Ranson,&nbsp;Aram Rojas,&nbsp;Sebastiaan Ceuppens,&nbsp;Robin Schmitz,&nbsp;Hao Liu,&nbsp;Nikhil V. Tirukkovalur,&nbsp;Mark Talamonti,&nbsp;Kenneth K. Lee,&nbsp;Herbert J. Zeh,&nbsp;Carl Schmidt,&nbsp;Brian A. Boone,&nbsp;Melissa Hogg,&nbsp;Amer H. Zureikat,&nbsp;Patricio M. Polanco,&nbsp;Alessandro Paniccia","doi":"10.1002/jso.70179","DOIUrl":"10.1002/jso.70179","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>Pancreatic ductal adenocarcinoma (PDAC) is characterized by limited survival rates, yet patients who achieve optimal CA19-9 response to neoadjuvant therapy (NAT) exhibit improved survival. This study examines the association between initial CA19-9 levels and survival in PDAC patients who achieved CA19-9 normalization with systemic chemotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective, multi-institutional analysis of patients with resectable/borderline-resectable PDAC, who underwent NAT and curative-intent pancreatectomy at the University of Pittsburgh Medical Center, University of Texas Southwestern Medical Center, NorthShore University, and West Virginia University To contexualize thi between 2010 and 2022, was performed. CA19-9 secretors (&gt; 37 U/mL, with total bilirubin &lt; 2) at diagnosis, with optimal response to NAT (normalization and &gt; 50% drop in CA19-9) were included. A cutoff for pre-NAT CA19-9 of 400 U/mL was determined to maximize sensitivity and specificity for survival benefit, and the cohort was accordingly divided into two groups. Kaplan–Meier and Cox proportional-hazards models were used for univariate and multivariable analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 134 patients were included, 32 (23.9%) had a pre-NAT CA19-9 ≥ 400U/mL. DFS and OS were considerably higher among patients with pre-NAT CA19-9 &lt; 400U/mL (median(95%CI) in months, DFS:19.8(16.0,33.4) versus 7.8(5.0,13.0); OS:49.0(34.5,70.7) versus 23.1(13.8,50.9)). On multivariable analysis, pre-NAT CA19-9 ≥ 400 U/mL was significantly associated with reduced DFS and OS (DFS:HR = 2.4, <i>p</i> = 0.001; OS:HR = 1.9, <i>p</i> = 0.028).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this select cohort of PDAC patients with optimal NAT response, pre-NAT CA19-9 ≥ 400U/mL is strongly associated with decreased DFS and OS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"133 2","pages":"177-185"},"PeriodicalIF":1.9,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Surgical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1